Calreticulin (CRT) engagement with CD91 fosters the maturation and activation of DCs, culminating in the cross-presentation of tumor antigens and the elicitation of tumor-specific cytotoxic T lymphocyte (CTL) responses. The gene discussed is LRP1; the disease is neoplasm.